Montpellier, November 17, 2021
NFL Biosciences: production agreement for its active ingredients with Diverchim
GMP (Good Manufacturing Practices) production of the active ingredients of NFL-101 and NFL-201
A long-term partnership to master and control manufacturing know-how
NFL Biosciences TO, biopharma companyceutical developant botanical drugs for the treatment of dependencies and addictions, and Diverchim, leading player in France in the development of point and the BPF production of original active ingredients, announcementnt the establishment of a partnership. Diverchim takes care of the production tobacco leaf protein liquid extracts and cannabis, making ups essentials from NFL-101, botanical drug candidate from NFL Biosciences in the treatment of l’tobacco addiction and NFL-201, intended for the treatment of cannabis dependence.
A PRODUCTION BPF ACTIVE PRINCIPLES THE NFL-101 AND NFL-201
The partnership between NFL Biosciences and Diverchim will consist in producing the active ingredient of NFL-101 for its use in additional clinical studies in the CESTO II study (Phase II / III).
The development plan put in place will also be applied to the preclinical development of the active ingredient of NFL-201, a drug candidate from NFL Biosciences for the treatment of cannabis addiction.
A LONG TERM PARTNERSHIP FOR MYCONTROL AND CONTROL MANUFACTURING KNOW-HOW
Thanks to this partnership, NFL Biosciences will secure control over the production of botanical extracts in order to anticipate future development and marketing needs after obtaining Marketing Authorizations.
Bruno Lafont, Deputy CEO and co-founder of NFL Biosciences: « We are very happy to implement this partnership with Diverchim, company who benefits from all expertise and know-how necessary for to accompany NFL Biosciences. Un new « month without tobacco » shows urgency and importance the development of NFL-101, natural drug candidate, which could constitute aweaning aid of prize1st intention for the smokers, wishing to quit smoking and Escape to their nicotine addiction ».
Pierre Charrier, Managing Director of Diverchim: “ Based on son organization certified Good Manufacturing Practices, Diverchim ensures full traceability, from the analysis of raw materials, as well as from the manufacturing follow-up until the release of the active ingredient. These assets have largely contributed to the establishment of this agreement with NFL Biosciences and we are proud to take part in this innovative approach to tobacco control. and cannabis addiction ».
FROM CANDIDATES MEDICAMENTS BOTANICALS TO COMBAT TOBACCO ADDICTIONS AND CANNABIS
NFL-101 is a clinically developed botanical drug candidate, composed of natural proteins extracted from tobacco leaves, and devoid of nicotine. NFL-101 has been the subject of the filing of two families of patents, as well as preclinical studies and a Phase I in highly dependent smokers, which demonstrated a significant reduction in the desire to smoke as well as long-term stops, without showing any toxicity. NFL-101 is derived from an extract that has been used successfully over the counter in over 10,000 smokers.
NFL-201 is a future drug candidate for the treatment of cannabis dependence, the consumption of which is frequently carried out in parallel with that of tobacco, as well as alcohol. The psychoactive THC molecule as well as the CBD will be removed from the extract during the manufacturing process, just like nicotine is from tobacco leaf extract for NFL-101.
About NFL Biosciences
NFL Biosciences is a Montpellier-based biopharmaceutical company developing a botanical drug candidate for smoking cessation. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, simplified and personalized alternative.
Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism.
Bruno Lafont – email@example.com – 04 11 93 76 67
Calyptus Agency – firstname.lastname@example.org – 01 53 65 68 68